Kevin Conroy/exactsciences.com
Aug 9, 2025, 19:03
Kevin Conroy: Exact Sciences Hits 1.3M Tests, Setting New Record
Kevin Conroy, Chairman and CEO of Exact Sciences, shared a post on LinkedIn:
“In Q2, the Exact Sciences team delivered 1.3 million test results, an all-time high, helping more people get the answers they need to make life-changing decisions.
We secured Medicare coverage in colorectal cancer for Oncodetect, our molecular residual disease test, and saw strong performance across Screening, Precision Oncology, and new launches. These achievements drove $811M in total revenue and led us to raise our full-year 2025 guidance.
We also announced an exclusive license agreement with Freenome to offer a blood-based colorectal cancer screening test, pending regulatory approval.
More posts featuring Kevin Conroy.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 9, 2025, 19:03
Aug 9, 2025, 18:55
Aug 9, 2025, 17:52
Aug 9, 2025, 17:47